GlassScriptPhysician profile
Philip Eliades
NPI 1861840290
$9,998.45
in general payments reported to CMS, 2019-2025
26 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $272 · 2021: $1,166 · 2022: $1,669 · 2023: $3,359 · 2024: $1,246 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,853 · Travel and Lodging: $837 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.02 |
| Travel and Lodging | $836.94 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,856.24 | 2019-2025 | |
| Biofrontera INC. | $1,490.83 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $1,241.21 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $750.50 | 2019-2024 | Olumiant, Taltz, Zepbound |
| Dermavant Sciences, INC. | $520.46 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $487.85 | 2020-2025 | Ilumya |
| Allergan, INC. | $478.04 | 2019-2022 | |
| Pfizer INC. | $404.62 | 2019-2024 | |
| Janssen Biotech, INC. | $402.38 | 2019-2025 | Tremfya |
| Genzyme Corporation | $356.49 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $317.90 | 2023-2025 | Ycanth |
| Novartis Pharmaceuticals Corporation | $270.98 | 2019-2025 | |
| Leo Pharma INC. | $264.57 | 2022-2024 | Adbry |
| Galderma Laboratories, L.P. | $219.44 | 2021-2025 | Aklief, Oracea, Twyneo |
| Ucb, INC. | $212.15 | 2020-2025 | Bimzelx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $157.33 | 2020-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $125.14 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $119.82 | 2022-2025 | Dupixent |
| Celgene Corporation | $91.00 | 2019 | |
| Arcutis Biotherapeutics, INC. | $67.48 | 2023-2024 | Zoryve |
| Organon LLC | $59.06 | 2025 | Nexplanon, Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.08 | 2024 | Cyltezo |
| Almirall LLC | $21.61 | 2021 | |
| Epi Health, LLC | $20.07 | 2021 | |
| Journey Medical Corporation | $19.07 | 2021 | |
| Dermira, INC. | $15.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Eliades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.